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Squamouscellcarcinoma(SCC)accountsforapproximately95%ofthemalignanttumorsofthevaginalvulvaandismostlyfound
in elderly women. The future numbers of patients with vulvar SCC is expected to rise, mainly because of the proportional increase
in the average age of the general population. Two diﬀerent pathways for vulvar SCC have been put forth. The ﬁrst pathway is
triggered by infection with a high-risk-type Human Papillomavirus (HPV). Integration of the HPV DNA into the host genome
leads to the development of a typical vulvar intraepithelial neoplasia (VIN), accompanied with overexpression of p14ARF and
p16INK4A. This lesion subsequently forms a warty- or basaloid-type SCC. The HPV vaccine is a promising new tool for prevention
of this HPV related SCC of the vulva. The second pathway is HPV-independent. Keratinizing SCC develops within a background
of lichen sclerosus (LS) through a diﬀerentiated VIN. It has a diﬀerent set of genetic alterations than those in the ﬁrst pathway,
including p53 mutations, allelic imbalances (AI), and microsatellite instability (MSI). Further clinical and basic research is still
required to understand and prevent vulvar SCC. Capsule. Two pathway for pathogenesis of squamous cell carcinoma of the value
are reviewed.
1.Introduction
Squamous cell carcinoma (SCC) accounts for only 5% of
the malignant tumors of the female genital tract, but it
represents 95% of vaginal vulvar tumors [1]. The incidence
of malignant vulvar tumors in the United States is 1.5per
100,000 women per year, and this incidence increases with
age. The average age at diagnosis is in the 7th to 8th decades
of life, with a future rise in absolute numbers of vulvar SCC
expected, mainly due to the proportional increase in the
average age of the general population [2].
Two diﬀerent types of vulvar SCC have been delineated,
each with their own precursors. The ﬁrst type is associated
with an infection with one of the high-risk types of Human
Papillomaviruses (HPV), and it primarily aﬀects younger
women. The other type is associated with a lichen sclerosus
(LS) condition, and it occurs predominantly in elderly
patientsindependentofanyHPVinfection[2].Althoughthe
pathogenesis of vulvar SCC has been investigated, it has not
been documented nearly as well as the pathogenesis of the
more common cervical SCC.
We herein give an overview, focusing on the molecular
eventsofthesetwodistinctHPV-associatedandindependent
pathways for the development of vulvar SCC.
2.ClinicalandPathological Featuresof
SCCand Its Precursors
2.1. SCC. Vulvar SCC accounts for 90% of vulvar cancers
and 5% of gynecological cancers. Patients usually present
with a vulvar mass, which may be pruritic or painful
or be associated with bleeding, and, occasionally, with a
groin mass. Clinical factors that have adverse prognostic
signiﬁcance include increased stage, older age, smoking, and
ﬁxed or ulcerated groin nodes [3].
The three main histological subtypes of vulvar SCC
are: warty, basaloid, and keratinizing (Table 1 and Fig-
ure 1). The predominant type, keratinizing, accounts for2 Journal of Skin Cancer
65%–80% of vulvar SCCs; the basaloid and warty types
of SCC account for the remaining 20%–35% [3]. The
keratinizing type usually occurs in postmenopausal women;
the warty/basaloid types tend to occur more often in
premenopausal or perimenopausal women. The keratinizing
type is usually formed by well, or moderately diﬀerentiated
cells with an absence of koilocytosis. There are usually one or
more adjacent epithelial lesions, including LS, squamous cell
hyperplasia (SCH), and diﬀerentiated vulvar intraepithelial
neoplasia (VIN) [3], which will each be described further in
the following sections.
The warty or basaloid types of SCC often accompany
a normal-type VIN. The basaloid type typically grows in
bands, sheets, or nests within a desmoplastic stroma, and
focal cytoplasmic maturation and keratinization may be
observed. The warty type exhibits invasion as bulbous or
irregular jagged nests, often with prominent keratinization.
The koilocytotic tumor cells have pleomorphic to bizarre,
often multiple, nuclei with irregular contours that vary from
hyperchromatic and shrunken to those with clumped or
smudged chromatin [3].
Other histological subtypes include verrucous carci-
noma, giant cell carcinoma, and acantholytic squamous
cell carcinoma. Verrucous carcinoma is highly diﬀerentiated
squamous carcinoma that has a verrucous pattern and
invades with a pushing border in the form of bulbous pegs of
neoplastic cells. Squamous cell carcinoma with tumor giant
cells is a variant of SCC characterized by multinucleated
tumor giant cells, large nuclei with prominent nucleoli, and
prominent eosinophilic cytoplasm. This variant is relatively
rare and is associated with a poor prognosis. The acan-
tholytic squamous cell carcinoma forms rounded spaces, or
pseudoacini, lined with a single layer of squamous cells.
Dyskeratotic and acantholytic cells are sometimes present in
the central lumen [4].
2.2. VIN. Various terms have been used to deﬁne the
precursors of vulvar SCC. Bowen ﬁrst reported on these
squamous intraepithelial lesions in 1912, and they are now
commonly referred to as Bowen’s disease; since then, a
myriad of clinical and histopathological terms have been
employed to describe these vulvar precancerous lesions [5].
The International Society for the Study of Vulvar Disease
(ISSVD) simpliﬁed the terminology for carcinoma in situ
and vulvar atypia in 1976; in 1986 they adopted the single
term of VIN and a 3-grade VIN system based on the
terminology from cervical intraepithelial neoplasia (CIN)
[5]. In VIN 1, maturation was present in the upper two-
thirds of the epithelium. In VIN 2, the dysplasia involves
the lower two-thirds of the epithelium, and in VIN 3, the
dysplasia extends into the upper third [5]. The terms of
warty, basaloid, and diﬀerentiated (simplex) are used in the
same way as for cervical SCC.
The most recent classiﬁcations are shown in Table 2.T h e
World Health Organization (WHO) classiﬁes VIN according
to the 3-grade system for both the warty/basaloid types and
the simplex type [7]. In 2004, ISSVD modiﬁed their VIN
terminology and suggested a 2-tier classiﬁcation: VIN usual
type and VIN diﬀerentiated type. Moreover, they decided to
abolish the term VIN 1. The term of VIN is now applied
only to the histologically high-grade squamous lesions that
were the former VIN 2 and VIN 3 or diﬀerentiated VIN
[5]. This revision was made based on the observation that
there was neither evidence that the morphologic spectrums
of VIN 1, 2, and 3 reﬂect a biologic continuum nor that
VIN 1 was a cancer precursor [2]. In 2005, Medeiros et
al. proposed a Bethesda-like grading system of low-grade
vulvar intraepithelial lesions (Low-grade VILs) and high-
grade vulvar intraepithelial lesions (High-grade VILs) [6].
Low-grade VILs correspond to lesions associated with low-
risk HPV infections. Condyloma acuminatum and discrete
raised lesions with minimal atypia and lacking the features
of dermatosis (VIN 1) were categorized into low-grade VIL
[6].
AsystematicreviewoftheprogressionratefromVIN3to
invasive SCC, after various clinical treatments, was reported
to be 3.3% [8]. Nine percent of 88 untreated patients
progressed to SCC during 12 to 96 months. Complete
regression of usual VIN 3 lesions were observed in 1.2%
of 3322 patients, mostly during the ﬁrst 10 months after
diagnosis, 41% of which remission was related to pregnancy.
Another study demonstrated that the overall percentage of
diﬀerentiated VIN lesions with subsequent diagnosis of SCC
was 32.8%, and that of usual type VIN was 5.7% [9]. The
median time for progression from usual type VIN to SCC
was 41.4 months whereas that from diﬀerentiated VIN to
SCC was signiﬁcantly shorter: 22.8 months (P = .005).
Another study demonstrated that the mean time from the
incidence of HPV infection to the development of VIN 1–3
was 18.5 months (95% conﬁdence interval, 13.4–23.6) [10].
The typical presentation of usual VIN is a pruritic, burn-
ing, or asymptomatic, white, red, or pigmented lesion. The
incidence of this form of VIN has almost doubled over the
past several decades, with a signiﬁcant increase in younger
women. The lesions of diﬀerentiated VIN usually range from
0.5to3.5cm,appearingassingleormultiplegray-whiteareas
with a rough surface or ill-deﬁned white plaques or nodules.
The lesions usually occur in postmenopausal women [3].
2.3. LS. LS runs a relapsing and remitting course and
presenting symptoms include pruritus, soreness, burning,
and irritation. Typically, the lesions are white plaques and
papules, often with areas of erythema hyperkeratosis, pallor,
and ulcer [2].
The histological features of lichen sclerosus (LS) include
a thinned epidermis with loss of normal rete pegs, basal
layer vacuolar changes and a paucity of melanocytes, and,
moreover, a wide band of homogeneous collagen below the
dermatoepidermal junction and a band-like lymphocytic
inﬁltrate below the homogenized area are present (Figure 1).
The dermis often shows variable degrees of edema [2].
LS most commonly aﬀects the anogenital area (85%
to 98%), with extragenital lesions occurring in 15% to
20% of the patients [11]. LS occurs at all ages; however, it
has a bimodal peak of incidence in prepubertal girls and
postmenopausal women [2]. According to a previous study,
1 out of 30 elderly women suﬀer from LS [12]. As association
of LS with autoimmune disorders has been demonstrated.Journal of Skin Cancer 3
Table 1:Characteristicsoftwotypesofsquamouscellcarcinomaofthevulva.(Characteristicsofthewarty/basaloidtypeandthekeratinizing
type of SCC of the vulva are shown).
warty or basaloid type keratinizing type
Frequency 20%–35% 65%–80%
Age Younger Older
55 (35–65) 77 (55–85)
Precursor warty or basaloid VIN Lichen sclerosus diﬀerentiated VIN
Molecular characteristics HPV integration p53 mutation
p14ARF ·p16INK4a overexpression Microsatellite instability
Prognosis better worse
(a) LS (b) SCC, diﬀerentiated type
(c) SCC, warty type (d) SCC, basaloid type
Figure 1: Examples of hematoxylin and eosin staining of vulvar lesions (×200) type.
According to previous studies, around 30% of the patients
have active autoimmune disease and autoantibodies were
detected in about half of the serum of the LS patients [2, 13–
16]. LS is considered to occur at sites of injured skin in
women with the susceptible immunophenotype who scratch
the area because of genital irritation [2].
The risk of development of vulvar SCC in women with
LS was shown to be 4% to 5% [11]. A previous review study
also estimated a 4.5% frequency of SCC arising in LS with an
i n t e r v a lo fa p p r o x i m a t e l y1 0y e a r s( 1 . 6 7t o1 2 . 5y e a r s )a f t e r
diagnosis of LS without SCC [17].
3. Mechanismsof Carcinogenesis
3.1. HPV-Related Carcinogenesis. Two distinct pathways,
HPV related and HPV independent, were proposed for
vulvar carcinogenesis (Figure 2). Warty/basaloid type SCC
develops through usual (warty/basaloid) type VIN triggered
by infection with high-risk type HPVs, predominantly
HPV−16 and −18 [2]. Usual type VIN lesions are observed
adjacent to greater than 10%–67% of the vulvar SCC
lesions [18]. A previous study showed that 69% to 100%
of warty/basaloid type SCC were positive for high-risk type
HPVs [19]. High-risk type HPVs were detected in 84% of 45
usual VIN cases [20]. Eighty-seven percent (13 of 15) of the
usual high-risk type HPV-positive VIN lesions were shown
t oe x p r e s sb o t hp 1 4 ARF (a cell-cycle regulator which mediates
p53 activation) and p16INK4A (a cyclin-dependent kinase
inhibitor) [21]. Hoevenaars showed that all 38 usual VIN
lesions exhibited positive p16INK4A immunohistochemical
staining, and that in all these cases a high MIB1 index was
observed. No expression of p53 and p16INK4A was detected
in normal epithelium of the vulva [20]. However, so far4 Journal of Skin Cancer
Normal vulvar epithelium
HPV infection
Usual VIN (warty/basaloid)
Polyclonal lesion
Integration of HPV DNA
Monoclonal lesion
Squamous cell carcinoma (warty/basaloid)
Lichen screlosus
(with/without squamous cell hyperplasia)
Diﬀerentiated VIN
Squamous cell carcinoma (keratinizing)
Figure 2: Pathogenesis of squamous cell carcinoma of the vulva. (Distinct pathways for carcinogenesis of keratinizing and warty/basaloid
types of vulvar SCC from normal epithelium through precursor lesions are demonstrated.)
Table 2: Classiﬁcations of vulvar intraepithelial neoplasia. (WHO,
ISSVD, and Bethesda-like classiﬁcations are shown.)
WHO (2003)
VIN 1,2,3 (warty type/basaloid type)
VIN 1,2,3 (simplex type)
ISSVD (2004)∗
VIN, usual type (VIN 2,3)
(a) warty type
(b) basaloid type
(c) mixed type
VIN 3, diﬀerentiated type (VIN 3)
Bethesda-like system [6]
Low-grade VIL (condyloma NIN 1)
High-grade VIL (VIN 2/VIN 3)
∗VIN1: abolished terminology.
little has been found concerning the mechanism of enhanced
expression of p14ARF and p16INK4A in the carcinogenesis of
vulvar SCC.
T h eH P Vv i r a lg e n ep r o d u c t sE 6a n dE 7i n t e r a c t
with host cell p53 and Rb proteins, resulting in p53
dysfunction and inactivation of Rb, respectively. In cervical
carcinogenesis triggered by high-risk type HPV infection,
E7 inhibits Rb, resulting in the release of active host E2F-
1, which positively regulates host p14ARF. E6 inhibits p53
function by binding with E6-AP ubiquitin ligase, and leads
to p14ARF upregulation via p53 degradation by negative
feedback mechanism [22, 23]. Functional inactivation of
Rb by E7 protein also leads to p16INK4A overexpression.
Taken together, p14ARF and p16INK4A were over-expressed
as a consequence of HPV E6 and E7 expression in cervical
carcinomas.
In carcinogenesis of HPV-related SCC, similar mecha-
nisms to cervical carcinogenesis seem to play an important
role. Degradation and inactivation of the tumor suppressor
genes p53 and Rb leads to absence of cell-cycle arrest and
hyperproliferationoftumorcells.Frequentdetectionofover-
expression of p14ARF and p16INK4A in VIN suggests that
degradation and inactivation of p53 and Rb are early events
in carcinogenesis of HPV-related SCC of the vulva.
3.1.1. Integration of High-Risk Type HPV DNA. In uterine
cervical carcinogenesis, integration of the high-risk type
HPV DNA into the host genome was demonstrated to be an
initial step for monoclonal expansion of dysplastic cells [24].
In the process of the integration, some parts of the E2 open
reading frame (ORF), which encode a 48-kd phosphorylated
protein involved in the regulation of viral DNA transcription
and replication, are usually disrupted or deleted from HPV
genome, causing up-regulation of the oncogenic E6 and E7
genes [25]. HPV integration sites were demonstrated to be
semirandomly distributed over the whole genome, with a
clear predilection for genomic fragile sites, but there was
no evidence for targeted disruption or functional alteration
of critical cellular genes by the integrated viral sequences.
The main function of HPV integration is considered to
be for the stabilization of viral oncogene transcription
[26, 27].
Similar mechanisms to those for cervical cancer seem
to play an important role during the development of
HPV-related vulvar SCC triggered by high-risk type HPV
infection. Integration of HPV-16 DNA, with deletion of the
E2 ORF in both the SCC portion and its adjacent VIN
3 lesions, which were all implied to be formed from a
single cell of origin through monoclonal expansion, was ﬁrst
demonstrated in a case of vulvar SCC by Ueda et al. [35].
Monoclonal composition was also demonstrated in 3 of 7
cases of VIN 1/2, and 12 of 13 VIN 3 cases in the study.
Later, additional supporting studies have also shown VIN 3
cases associated with infection of HPV in an integrated form
[28, 29].Journal of Skin Cancer 5
3.1.2. HPV Vaccine. The HPV vaccine is a tremendously
promising new tool for the prevention of HPV-related SCC
of the vulva, as it has already been for the cervix. The
FUTURE I study has demonstrated that a prophylactic
quadrivalent HPV-(6/11/16/18) L1 VLP vaccine signiﬁcantly
reduced the incidence of HPV-associated anogenital diseases
in young women [30]. The prophylactic eﬃcacy in the study
was 100% for vulvar condyloma, VIN 1, and VIN 2/3 in the
per-protocol population. Other studies also demonstrated
that the prophylactic quadrivalent HPV vaccine completely
protected VIN 2/3 [31, 32].
Interestingly, a series of 3-4 vaccinations against a
synthetic long-peptide of the HPV-16 oncoproteins E6 and
E7 was shown to be therapeutically eﬀective for HPV-16-
positive VIN 3 patients [33]. At 3 months after the last
vaccination, 5 (25%) of 20 patients had complete remission
of the lesion, and HPV-16 was no longer detected in 4
cases (20%). At 12 month of followup, 9 (47%) of 19
patients had a complete response with tolerable adverse
eﬀects. The patients who had a complete response at 3
months demonstrated a signiﬁcantly stronger interferon-γ-
associated proliferative CD4+T-cell response and a broader
response of CD8+ interferon-γ T-cells. A phase II clinical
trial of the topical immune-modulator imiquimod, followed
by therapeutic HPV-16 vaccine using a fusion protein of
HPV-16 E6E7L2 on 19 cases with VIN 2/3, demonstrated
that complete regression of VIN 2/3 lesions was observed in
63% of the cases (12 of 19) [34].
3.2. HPV-Independent Carcinogenesis. The majority of vul-
var SCC are considered to occur in elderly women through
diﬀerentiated VIN in a background of LS [2]. High-risk type
HPVs were detected in none of 75 diﬀerentiated VIN cases
[20]. They also showed that all 75 diﬀerentiated VIN lesions
exhibited negative p16 immunohistochemical staining, and
a low MIB1 index was observed in 96% (72 of 75 cases)
of the cases [20]. No relationship between HPV infection
and LS was found in these women [2, 21]. These results
stronglysuggestthat anHPV-independent pathwayexists for
carcinogenesis of vulvar SCC from LS through diﬀerentiated
VIN; however, the mechanism of HPV-independent carcino-
genesis has not yet been fully elucidated.
We have previously demonstrated that 2 of 6 LS lesions
exhibited monoclonality, implying that certain important
molecular alterations might occur in some LS lesions well
before histologically apparent malignant transformation to
diﬀerentiated VIN or keratinizing SCC occurs [35]. Rolfe et
al. showed that 10 of 12 LS-associated SCCs exhibited a p53
mutation, and in 7 of those 10 cases LS lesions exhibited
the p53 mutation at the same codon as in the SCC lesions,
suggesting that a p53 mutation is possibly involved early
in the HPV-independent pathway of vulvar carcinogenesis
[36]. Somatic mutation of PTEN was also demonstrated in
some cases of vulvar SCC and VIN, suggesting that PTEN
mutation possibly played a role early in the carcinogenesis of
vulvar SCC [37]. Pinto et al. found that an allelic imbalance
(AI) was present in 67%, 53%, and 43% of usual type
VIN, diﬀerentiated VIN and LSs, respectively, and that
microsatellite instability (MSI) was detected in 3 (20%) of
15 diﬀerentiated VIN, and 2 (12%) of 17 LS, but none of
usualtype VIN, implying thatthese molecularalterations are
also possibly early events in vulvar carcinogenesis, and that
MSI may play a critical role for malignant potential of LS
[38].
A recent study demonstrated more frequent hyperme-
thylation of RASSF2A, MGMT, and TSP-1 genes in SCC
associated with LS than in SCC not associated with LS,
suggestingapossibleroleofthesegenesinHPV-independent
carcinogenesis [39].
A fraction of squamous cell hyperplasia (SCH) lesions
were shown to be monoclonal in composition [35] and p53
mutation, AI, and MSI were observed in 22%, 50% and
20%, respectively, of SCH cases [36, 38]. SCH with atypia
might be a precursor of SCC; however, SCH without atypia
is, currently, not regarded as a direct precursor of SCC.
Relationship between SCH and keratinizing SCC is still to be
determined [2, 38].
4. Conclusions
Two distinct pathways leading to vulvar SCC have been sug-
gested. One is a pathway primarily linked to infection with
high-risk types of HPV; the other is an HPV-independent
scenario. Mechanisms similar to those that drive cervical
carcinogenesis possibly play an important role in HPV-
related carcinogenesis of vulvar SCC. HPV prophylactic and
therapeutic vaccines are both promising to prevent HPV
infection and prevent development of warty/basaloid type
SCC from its precursor, the usual type VIN. On the other
hand, keratinizing type vulvar SCC, which by far represents
the majority of vulvar SCC, occurs independently from HPV
infection in a background of LS. The mechanism of carcino-
genic progression forward from LS in this second pathway
has not fully delineated, and it is not yet clear whether
medical treatments of LS prevent malignant transformation.
Further clinical and basic research into these important areas
is still required.
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